Controlled-release Vaginal Ring drug-delivery Systems: a Key Strategy for the Development of Effective HIV Microbicides

• Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2009. AIDS epidemic update – November 2009. UNAIDS, Geneva, Switzerland (2009).
   Google Scholar
• Miller CJ , McGheeJR, GardnerMB. Biology of disease: mucosal immunity, HIV transmission, and AIDS. Lab. Invest.68(2), 129–142 (1992).
   Web of Science ®Google Scholar
• Kiyono H , MillerCJ, LuYet al. The common mucosal immune system for the reproductive tract: basic principles applied toward an AIDS vaccine. Adv. Drug Deliv. Rev. 18(1), 23–51 (1995).
   Web of Science ®Google Scholar
• Grant AD , De Cock KM. HIV infection and AIDS in the developing world. In: ABC of AIDS. Adler MW (Ed.). BMJ Publishing Group, London, UK, 59–64 (2001).
   Google Scholar
• Nicolosi A , Corrêa Leite ML, Musicco M, Arici C, Gavazzeni G, Lazzarin A. The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus – a study of 730 stable couples. Epidemiology5(6), 570–575 (1994).
   PubMed Web of Science ®Google Scholar
• Woolfson AD , MalcolmRK, TonerCFet al. Potential use of vaginal rings for prevention of heterosexual transmission of HIV: a controlled-release strategy for HIV microbicides. Am. J. Drug Del. 4(1), 7–20 (2006).
   Google Scholar
• Wira C , FaheyJ. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS22(15), 1909–1917 (2008).
   PubMed Web of Science ®Google Scholar
• European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ304(6830), 809–813 (1992).
   PubMed Web of Science ®Google Scholar
• Padian NS , ShiboskiSC, GlassSO, VittinghoffE. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. Am. J. Epidemiol.146(4), 350–357 (1997).
   PubMed Web of Science ®Google Scholar
• Royce RA , SeñaA, CatesW, CohenMS. Current concepts – sexual transmission of HIV. N. Engl. J. Med.336(15), 1072–1078 (1997).
   PubMed Web of Science ®Google Scholar
• Johnston MI , FauciAS. An HIV vaccine – challenges and prospects. N. Engl. J. Med.359(9), 888–890 (2008).
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S , PitisuttithumP, NitayaphanSet al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361(23), 2209–2220 (2009).
   PubMed Web of Science ®Google Scholar
• Haut LH , ErtlHCJ. Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine. J. Leukocyte Biol.86(4), 779–793 (2009).
   PubMed Web of Science ®Google Scholar
• McGowan I . Microbicides: a new frontier in HIV prevention. Biologicals34(4), 241–255 (2006).
   PubMed Web of Science ®Google Scholar
• MacPhail C , Terris-PrestholtF, KumaranayakeL, NgoakoP, WattsC, ReesH. Managing men: women‘s dilemmas about overt and covert use of barrier methods for HIV prevention. Cult. Health Sex.11(5), 485–497 (2009).
   PubMed Web of Science ®Google Scholar
• Stone A , HarrisonPF. Microbicides – ways forward. Alliance for Microbicide Development. Silver Spring, MD, USA (2010).
   Google Scholar
• Rohan LC , SassiAB. Vaginal drug-delivery systems for HIV prevention. AAPS J.11(1), 78–87 (2009).
   PubMed Web of Science ®Google Scholar
• das Neves J , BahiaMF. Gels as vaginal drug-delivery systems. Int. J. Pharm.318(1–2), 1–14 (2006).
   PubMed Web of Science ®Google Scholar
• Van Damme L , RamjeeG, AlaryMet al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360(9338), 971–977 (2002).
   PubMed Web of Science ®Google Scholar
• Moore JP , ShattockRJ. Preventing HIV-1 sexual transmission – not sexy enough science, or no benefit to the bottom line? J. Antimicrob. Chemoth.52(6), 890–892 (2003).
   PubMed Web of Science ®Google Scholar
• Keller MJ , MesquitaPMM, TorresNMet al. Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials. PLoS ONE 5(1), e8781 (2010).
   PubMed Web of Science ®Google Scholar
• Skoler-Karpoff S , RamjeeG, AhmedKet al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372(9654), 1977–1987 (2008).
   PubMed Web of Science ®Google Scholar
• Nuttall J . Microbicides in the prevention of HIV infection – current status and future directions. Drugs70(10), 1231–1243 (2010).
   PubMed Web of Science ®Google Scholar
• Ramjee G . Microbicide research: current and future directions. Curr. Opin. HIV AIDS5(4), 316–321 (2010).
   PubMed Web of Science ®Google Scholar
• Ludovici DW , De Corte BL, Kukla MJ et al. Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogs. Bioorg. Med. Chem. Lett.11(17), 2235–2239 (2001).
   PubMed Web of Science ®Google Scholar
• Di Fabio S , Van Roey J, Giannini G et al. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS17(11), 1597–1604 (2003).
   PubMed Web of Science ®Google Scholar
• Van Herrewege Y , MichielsJ, Van Roey J et al.In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob. Agents Ch.48(1), 337–339 (2004).
   PubMed Web of Science ®Google Scholar
• Malcolm RK , WoolfsonAD, TonerCF, MorrowRJ, McCullaghSD. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J. Antimicrob. Chemoth.56(5), 954–956 (2005).
   PubMed Web of Science ®Google Scholar
• Neurath AR , StrickN, LiYY. Role of seminal plasma in the anti-HIV-activity of candidate microbicides. BMC Infect. Dis.6(150), DOI: 10.1186/1471-2334-6-150 (2006) (Epub ahead of print).
   Google Scholar
• Woolfson AD , MalcolmRK, MorrowRJ, TonerCF, McCullaghSD. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int. J. Pharm.325(1–2), 82–89 (2006).
   PubMed Web of Science ®Google Scholar
• Gupta KM , PearceSM, PoursaidAEet al. Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J. Pharm. Sci. 97(10), 4228–4239 (2008).
   PubMed Web of Science ®Google Scholar
• Nuttall JP , ThakeDC, LewisMG, FerkanyJW, RomanoJW, MitchnickMA. Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days. Antimicrob. Agents Ch.52(3), 909–914 (2008).
   PubMed Web of Science ®Google Scholar
• Fletcher P , HarmanS, AzijnHet al. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob. Agents Ch. 53(2), 487–495 (2009).
   PubMed Web of Science ®Google Scholar
• Herrera C , CranageM, McGowanI, AntonP, ShattockR. Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob. Agents Ch.53(5), 1797–1807 (2009).
   PubMed Web of Science ®Google Scholar
• Saxena BB , HanYA, FuDet al. Sustained release of microbicides by newly engineered vaginal rings. AIDS 23(8), 917–922 (2009).
   PubMed Web of Science ®Google Scholar
• Johnson TJ , GuptaKM, FabianJ, AlbrightTH, KiserPF. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur. J. Pharm. Sci.39(4), 203–212 (2010).
   PubMed Web of Science ®Google Scholar
• Lederman MM , OffordRE, HartleyO. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat. Rev. Immunol.6(5), 371–382 (2006).
   PubMed Web of Science ®Google Scholar
• Patton DL , SweeneyYTC, BalkusJEet al. Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations. Antimicrob. Agents Ch. 51(5), 1608–1615 (2007).
   PubMed Web of Science ®Google Scholar
• Buckheit RW , WatsonKM, MorrowKM, HamAS. Development of topical microbicides to prevent the sexual transmission of HIV. Antivir. Res.85(1), 142–158 (2010).
   PubMed Web of Science ®Google Scholar
• Barbaro G , ScozzafavaA, MastrolorenzoA, SupuranCT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr. Pharm. Design11(14), 1805–1843 (2005).
   PubMed Web of Science ®Google Scholar
• Mayer KH , MaslankowskiLA, GaiFet al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 20(4), 543–551 (2006).
   PubMed Web of Science ®Google Scholar
• Parikh UM , DobardC, SharmaSet al. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J. Virol. 83(20), 10358–10365 (2009).
   PubMed Web of Science ®Google Scholar
• Rohan LC , MonclaBJ, Kunjara Na Ayudhya RP et al.In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS ONE5(2), e9310 (2010).
   PubMed Web of Science ®Google Scholar
• Högberg M , SahlbergC, EngelhardtPet al. Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogs. J. Med. Chem. 42(20), 4150–4160 (1999).
   PubMed Web of Science ®Google Scholar
• D‘Cruz OJ , UckunFM. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J. Antimicrob. Chemoth.57(3), 411–423 (2006).
   PubMed Web of Science ®Google Scholar
• Fernández-Romero JA , ThornM, TurvilleSGet al. Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex. Transm. Dis. 34(1), 9–14 (2007).
   PubMed Web of Science ®Google Scholar
• Balzarini J , Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet369(9563), 787–797 (2007).
   PubMed Web of Science ®Google Scholar
• Abdool Karim Q , Abdool Karim SS, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science329(5996), 1168–1174 (2010).
   PubMed Web of Science ®Google Scholar
• Woolfson AD , MalcolmRK, GallagherR. Drug delivery by the intravaginal route. Crit. Rev. Ther. Drug17(5), 509–555 (2000).
   PubMed Web of Science ®Google Scholar
• Malcolm RK . The intravaginal ring. In: Modified-Release Drug Delivery Technology. Rathbone MJ, Hadgraft J, Roberts MS (Eds). Marcel Dekker Inc., NY, USA, 775–790 (2003).
   Google Scholar
• Brache V , Alvarez-SanchezF, FaundesA, JackaniczT, MishellDR, LähteenmäkiP. Progestin-only contraceptive rings. Steroids65(10–11), 687–691 (2000).
   PubMed Web of Science ®Google Scholar
• Dieben TOM , RoumenFJME, ApterD. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet. Gynecol.100(3), 585–593 (2002).
   PubMed Web of Science ®Google Scholar
• Ayton RA , DarlingGM, MurkiesALet al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br. J. Obstet. Gynaec. 103(4), 351–358 (1996).
   PubMedGoogle Scholar
• Barentsen R , van de Weijer PHM, Schram JHN. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur. J. Obstet. Gyn. R. B.71(1), 73–80 (1997).
   PubMed Web of Science ®Google Scholar
• Hardy E , HeblingEM, SousaMH, AlmeidaAF, AmaralE. Delivery of microbicides to the vagina: difficulties reported with the use of three devices, adherence to use and preferences. Contraception76(2), 126–131 (2007).
   PubMed Web of Science ®Google Scholar
• Chien YW . Novel Drug Delivery Systems (2nd Edition). Marcel Dekker Inc., NY, USA (1992).
   Google Scholar
• Fraser IS , LacarraM, MishellDRet al. Vaginal epithelial surface appearances in women using vaginal rings for contraception. Contraception 61(2), 131–138 (2000).
   PubMed Web of Science ®Google Scholar
• Dragonas C , MaltarisT, BinderHet al. Progesterone bioavailability with a progesterone-releasing silicone vaginal ring in IVF candidates. Eur. J. Med. Res. 12(6), 264–267 (2007).
   PubMed Web of Science ®Google Scholar
• Lawrence EL , TurnerIG. Materials for urinary catheters: a review of their history and development in the UK. Med. Eng. Phys.27(6), 443–453 (2005).
   PubMed Web of Science ®Google Scholar
• Shastri PV . Toxicology of polymers for implant contraceptives for women. Contraception65(1), 9–13 (2002).
   PubMed Web of Science ®Google Scholar
• Russell JA , MalcolmRK, CampbellK, WoolfsonAD. High-performance liquid chromatographic determination of 17β-estradiol and 17β-estradiol-3-acetate solubilities and diffusion coefficients in silicone elastomeric intravaginal rings. J. Chromatogr. B744(1), 157–163 (2000).
   PubMedGoogle Scholar
• Ballagh SA . Vaginal rings for menopausal symptom relief. Drug. Aging21(12), 757–766 (2004).
   PubMed Web of Science ®Google Scholar
• Malcolm RK , McCullaghSD, MorrowRJ, WoolfsonAD. Vagina and uterus as drug-absorbing organs. In: Enhancement in Drug Delivery. Touitou E, Barry BW (Eds). CRC Press, FL, USA, 395–440 (2006).
   Google Scholar
• Henriksson L , StjernquistM, BoquistL, CedergrenI, SelinusI. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring®) in postmenopausal women with symptoms and signs of urogenital aging. Am. J. Obstet. Gynecol.174(1), 85–92 (1996).
   PubMed Web of Science ®Google Scholar
• Massai R , MirandaP, ValdesPet al. Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women. Contraception 60(1), 9–14 (1999).
   PubMed Web of Science ®Google Scholar
• Massai R , DíazS, JackaniczT, CroxattoHB. Vaginal rings for contraception in lactating women. Steroids65(10–11), 703–707 (2000).
   PubMed Web of Science ®Google Scholar
• Massai R , QuinterosE, ReyesMVet al. Extended use of a progesterone-releasing vaginal ring in nursing women: a Phase II clinical trial. Contraception 72(5), 352–357 (2005).
   PubMed Web of Science ®Google Scholar
• Zegers-Hochschild F , BalmacedaJP, FabresCet al. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation. Hum. Reprod. 15(10), 2093–2097 (2000).
   PubMed Web of Science ®Google Scholar
• Timmer CJ , MuldersTMT. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin. Pharmacokinet.39(3), 233–242 (2000).
   PubMed Web of Science ®Google Scholar
• Breitenbach J . Melt extrusion: from process to drug-delivery technology. Eur. J. Pharm. Biopharm.54(2), 107–117 (2002).
   PubMed Web of Science ®Google Scholar
• van Laarhoven JAH , KruftMAB, VromansH. Effect of supersaturation and crystallization phenomena on the release properties of a controlled release device based on EVA copolymer. J. Control. Release82(2–3), 309–317, (2002).
   PubMed Web of Science ®Google Scholar
• van Laarhoven JAH , KruftMAB, VromansH. In vitro release properties of etonogestrel and ethinyl estradiol from a contraceptive vaginal ring. Int. J. Pharm.232(1–2), 163–173 (2002).
   PubMed Web of Science ®Google Scholar
• Higuchi T . Mechanism of sustained-action medication – theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J. Pharm. Sci.52(12), 1145–1149 (1963).
   PubMed Web of Science ®Google Scholar
• Malcolm K , WoolfsonD, RussellJ, TallonP, McAuleyL, CraigD. Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings. J. Control. Release90(2), 217–225 (2003).
   PubMed Web of Science ®Google Scholar
• Crank J . The Mathematics of Diffusion. Oxford at the Clarendon Press, London, UK (1956).
   Google Scholar
• Romano J , VarianoB, CoplanP, Van Roey J, Douville K, Rosenberg Z. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res. Hum. Retroviruses25(5), 483–488 (2009).
   PubMed Web of Science ®Google Scholar
• Nel A , SmytheS, YoungKet al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J. Acquir. Immune Defic. Syndr. 51(4), 416–423 (2009).
   PubMed Web of Science ®Google Scholar
• Morrow RJ , DonnellyL, CurranRMet al. A novel vaginal ring device for the sustained delivery of recombinant C-clade HIV-1 CN54gp140. Presented at: AIDS Vaccine 2009. Paris, France, 19–22 September 2009.
   Google Scholar
• Promadej-Lanier N , SmithJM, SrinivasanPet al. Development and evaluation of a vaginal ring device for sustained delivery of HIV microbicides to non-human primates. J. Med. Primatol. 38(4), 263–271 (2009).
   PubMed Web of Science ®Google Scholar
• Veazey RS , ShattockRJ, PopeMet al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9(3), 343–346 (2003).
   PubMed Web of Science ®Google Scholar
• Shively CA , WoodCE, RegisterTCet al. Hormone therapy effects on social behavior and activity levels of surgically postmenopausal cynomolgus monkeys. Psychoneuroendocrinology 32(8–10), 981–990 (2007).
   PubMed Web of Science ®Google Scholar
• Wood CE , RegisterTC, LeesCJ, ChenH, KimreyS, ClineJM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res. Tr.101(2), 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Wallace GS , Cheng-MayerC, SchitoMLet al. Human immunodeficiency virus type 1 nucleocapsid inhibitors impede trans infection in cellular and explant models and protect nonhuman primates from infection. J. Virol. 83(18), 9175–9182 (2009).
   PubMed Web of Science ®Google Scholar
• Yu RR , ChengAT, LagenaurLAet al. A Chinese rhesus macaque (Macaca mulatta) model for vaginal Lactobacillus colonization and live microbicide development. J. Med. Primatol. 38(2), 125–136 (2009).
   PubMed Web of Science ®Google Scholar
• Moss J , SmithJ, MaloneAMet al. In vitro and in vivo release of tenofovir from silicone intravaginal rings. Presented at: Microbicides: Building Bridges in HIV Prevention. Pittsburgh, PA, USA, 22–25 May 2010.
   Google Scholar
• Moss J , BaumM, MaloneAet al. In vitro release of tenofovir and acyclovir from a silicone vaginal ring platform. Presented at: Microbicides: Building Bridges in HIV Prevention. Pittsburgh, PA, USA, 22–25 May 2010.
   Google Scholar
• Han YA , SinghM, SaxenaBB. Development of vaginal rings for sustained release of nonhormonal contraceptives and anti-HIV agents. Contraception76(2), 132–138 (2007).
   PubMed Web of Science ®Google Scholar
• Nel AA , CoplanP, van de Wijgert JH et al. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS23(12), 1531–1538 (2009).
   PubMed Web of Science ®Google Scholar
• Martinez J , CoplanP, WainbergMA. Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies? Antivir. Res.71(2–3), 343–350 (2006).
   PubMed Web of Science ®Google Scholar
• Hughes A , BarberT, NelsonM. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. J. Infection57(1), 1–10 (2008).
   PubMed Web of Science ®Google Scholar
• Shattock R , SolomonS. Microbicides – aids to safer sex. Lancet363(9414), 1002–1003 (2004).
   PubMed Web of Science ®Google Scholar
• Loxley A , GokhaleA, McConnellJ, OkohO, EdwardsKL, MitchnickM. Combination ethylene vinyl acetate intravaginal vaginal rings containing dapivirine and maraviroc. Presented at: Microbicides: Building Bridges in HIV Prevention. Pittsburgh, PA, USA, 22–25 May 2010.
   Google Scholar
• McBride M , BoydP, FetherstonSet al. Preclinical stability evaluation of vaginal rings containing dapivirine and maraviroc. Presented at: Microbicides: Building Bridges in HIV Prevention. Pittsburgh, PA, USA, 22–25 May 2010.
   Google Scholar
• Berthoux L , PéchouxC, DarlixJL. Multiple effects of an anti-human immunodeficiency virus nucleocapsid inhibitor on virus morphology and replication. J. Virol.73(12), 10000–10009 (1999).
   PubMed Web of Science ®Google Scholar
• Rice WG , TurpinJA, SchaefferCAet al. Evaluation of selected chemotypes in coupled cellular and molecular target-based screens identifies novel HIV-1 zinc finger inhibitors. J. Med. Chem. 39(19), 3606–3616 (1996).
   PubMed Web of Science ®Google Scholar
• Srivastava P , SchitoM, FattahRJet al. Optimization of unique, uncharged thioesters as inhibitors of HIV replication. Bioorgan. Med. Chem. 12(24), 6437–6450 (2004).
   PubMed Web of Science ®Google Scholar
• Veazey RS , KlassePJ, KetasTJet al. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J. Exp. Med. 198(10), 1551–1562 (2003).
   PubMed Web of Science ®Google Scholar
• Veazey RS , SpringerMS, MarxPA, DufourJ, KlassePJ, MooreJP. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat. Med.11(12), 1293–1294 (2005).
   PubMed Web of Science ®Google Scholar
• Veazey RS , KlassePJ, SchaderSMet al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438(7064), 99–102 (2005).
   PubMed Web of Science ®Google Scholar
• Eggink D , LangedijkJPM, BonvinAMJJet al. Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J. Biol. Chem. 284(39), 26941–26950 (2009).
   PubMed Web of Science ®Google Scholar
• Cerini F , LandayA, GichingaCet al. Chemokine analogs show suitable stability for development as microbicides. J. Acquir. Immune Defic. Syndr. 49(5), 472–476 (2008).
   PubMed Web of Science ®Google Scholar
• Ham AS , CostMR, SassiAB, DezzuttiCS, RohanLC. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm. Res.26(3), 502–511 (2009).
   PubMed Web of Science ®Google Scholar
• Major I , LowryD, MalcolmK, WoolfsonD, CohenJ, LaBarreP. Development of a microbicide-releasing SILCS diaphragm. Presented at: Microbicides: Building Bridges in HIV Prevention. Pittsburgh, PA, USA, 22–25 May 2010.
   Google Scholar
• Yang CC , MaravillaKR, Kilbourne-BrookM, AustinG. Magnetic resonance imaging of SILCS diaphragm: anatomical considerations and corroboration with clinical fit. Contraception76(3), 238–244 (2007).
   PubMed Web of Science ®Google Scholar
• Schwartz JL , BallaghSA, CreininMDet al. SILCS diaphragm: postcoital testing of a new single-size contraceptive device. Contraception 78(3), 237–244 (2008).
   PubMed Web of Science ®Google Scholar
• Romano JW , NuttallJ, SmytheS, NelA. Dapivirine vaginal ring design and drug load effects on in vitro drug release and intravaginal drug distribution in women. Presented at: Microbicides: Building Bridges in HIV Prevention. Pittsburgh, PA, USA, 22–25 May 2010.
   Google Scholar
• Lowry D , FetherstonS, McConvilleC, WoolfsonD, MalcolmK. Silicone elastomer rings for sustained delivery of HIV microbicides: correlating historical in vitro and in vivo release data. Presented at: Microbicides: Building Bridges in HIV Prevention. Pittsburgh, PA, USA, 22–25 May 2010.
   Google Scholar
• Clark J , NagarajaU, TuitupouAet al. Sustained delivery of tenofovir from polyurethane intravaginal rings. Presented at: Microbicides: Building Bridges in HIV Prevention. Pittsburgh, PA, USA, 22–25 May 2010.
   Google Scholar
• Mawson P , SingerR, MenonRet al. Development of silicone vaginal rings for delivery of MIV-150 as a microbicide. Presented at: Microbicides: Building Bridges in HIV Prevention. Pittsburgh, PA, USA, 22–25 May 2010.
   Google Scholar
• McConville C , FriendD, WoolfsonD, MalcolmK. Safety testing of silicone elastomer matrix vaginal rings containing UC781 and Tween 80 using epivaginal (VEC-606) tissues. Presented at: Microbicides: Building Bridges in HIV Prevention. Pittsburgh, PA, USA, 22–25 May 2010.
   Google Scholar
• McConville C , FriendD, WoolfsonD, MalcolmK. A two-compartment in vitro release model for the testing of HIV microbicide formulations. Presented at: Microbicides: Building Bridges in HIV Prevention. Pittsburgh, PA, USA, 22–25 May 2010.
   Google Scholar
• Ho EA , TuitupouA, ElgendyH, ClarkMR, FriendDR, KiserPF. A polyurethane intravaginal ring for the delivery of UC781. Presented at: Microbicides: Building Bridges in HIV Prevention. Pittsburgh, PA, USA, 22–25 May 2010.
   Google Scholar
• Damian FR , HoEA, ClarkMR, FriendDR, KiserPF. Dual protection polyurethane intravaginal rings for the simultaneous delivery of levonorgestrel and UC781. Presented at: Microbicides: Building Bridges in HIV Prevention. Pittsburgh, PA, USA, 22–25 May 2010.
   Google Scholar
• Fetherston S , MalcolmK, WoolfsonD, LaceyC, ShattockR. Formulation development of matrix-type silicone elastomer vaginal rings containing protease inhibitors. Presented at: Microbicides: Building Bridges in HIV Prevention. Pittsburgh, PA, USA, 22–25 May 2010.
   Google Scholar
• Fetherston S , MalcolmK, WoolfsonD, Le Grand R, Bosquet N. In vivo safety study in Macacafascicularis on matrix-type silicone elastomer vaginal rings loaded with saquinavir. Presented at: Microbicides: Building Bridges in HIV Prevention. Pittsburgh, PA, USA, 22–25 May 2010.
   Google Scholar
• Ugaonkar S , WatsonKM, BuckheitRW Jr, Kiser PF. Delivery of a SAMT (NCp7 inhibitor) from an intravaginal ring. Presented at: Microbicides: Building Bridges in HIV Prevention. Pittsburgh, PA, USA, 22–25 May 2010.
   Google Scholar
• Johnson T , SrinivasanP, AlbrightTet al. Safety and pharmacokinetics of a pyrimidinedione reverse transcriptase inhibitor in pig-tailed macaques using elastomeric intravaginal rings. Presented at: Microbicides: Building Bridges in HIV Prevention. Pittsburgh, PA, USA, 22–25 May 2010.
   Google Scholar
• Malcolm K , LowryD, GreenLet al. Pre-treatment with Depo-Provera modifies the pharmacokinetics of CMPD167 in rhesus macaques following vaginal ring administration. Presented at: Microbicides: Building Bridges in HIV Prevention. Pittsburgh, PA, USA, 22–25 May 2010.
   Google Scholar
• Clark JT , KaurM, KiserPF. Design of an intravaginal ring for the simultaneous delivery of IQP-0528 and tenofovir. Presented at: Microbicides: Building Bridges in HIV Prevention. Pittsburgh, PA, USA, 22–25 May 2010.
   Google Scholar

Patent

• Duncan GW: US3545439 (1970).
   Google Scholar

Websites

• International Partnership for Microbicides. Initiation of the first safety trial in africa of an antiretroviral-containing vaginal ring designed to prevent HIV/AIDS. www.ipmglobal.org/news_room/english/statements/2010/20100608_safety_trial.htm (Accessed 15th June 2010)
   Google Scholar
• AVAC: Global Advocacy for HIV Prevention. Microbicides clinical trials table. www.avac.org/ht/d/sp/i/3512/pid/3512 (Accessed 27th August 2010)
   Google Scholar
• Molinspiration: calculation of molecular properties and drug-likeness. www.molinspiration.com/cgi-bin/properties (Accessed 17th September 2010)
   Google Scholar